Pulsus
Pulsus health tech
44 2033180199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Awards Nomination
Flyer image
25+ Million Website Visitors

Antianginal Agents New Findings

An antianginal is a drug employed in the treatment of angina pectoris, a symptom of ischaemic heart disease.

Drugs used are nitrates, beta blockers, or calcium channel blockers.

Nitrates cause dilation of the blood vessels by stimulating the endothelium-derived relaxing factor (EDRF).

Effective treatment of coronary artery disease requires a variety of distinct goals: controlling symptomatic angina, decreasing the adverse events associated with ischemia, and providing vascular protection against the atherosclerotic process. While there are a number of treatment possiblities for controlling symptomatic angina, along with medical therapy using beta blockers, calcium channel blockers, and nitrates and coronary revascularization, there are a significant number of patients who may benefit from a therapeutic mechanism of action different than those related with traditional antianginal therapy.

Ranolazine and ivabradine are newer, nontraditional antianginal medication used for the treatment of symptomatic angina within the setting of chronic, stable ischemic heart disease. Ranolazine is approved in U.S. and in Europe as for the treatment both as first line therapy and as add-on therapy in addition to standard medical therapy. In Europe, Ivabradine is approved for use but it is not in the U.S.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Medical Sciences

 
Google Scholar citation report
Citations : 1023

Journal of Heart Research received 1023 citations as per Google Scholar report

Flyer image

Indexed In

Read More
pulsus-health-tech
Top